Blog

Navigating the Regulatory Landscape of Rare Disease Drug Development
Recognizing Rare Disease Day and Its Impact. February 28, 2025, marks Rare Disease Day – a global initiative dedicated to raising awareness and driving change for the 300 million people worldwide living with a rare disease, along with their families and carers.

US growth journey: boosting the Boyds brand stateside
To meet growing demand for our expertise and services in the US, Boyds established a physical presence stateside in 2021, recruiting US regulatory and program management professionals to our team. As we head into 2025, we take a look back at Boyds’ US growth journey to date.

Navigating the complex regulatory landscape of medical devices in the EU
In this blog, Eamonn McGowran, Associate Director of Regulatory Affairs at Boyds, discusses the changes and key considerations for developers navigating the regulations, especially when managing combination products that integrate both devices and medicinal products.

EU AI Act: considerations for medical device developers
In this blog, Eamonn McGowran, Associate Director of Regulatory Affairs at Boyds explains the scope of the Act and key considerations for medical device developers.

Why work with an Interim Chief Medical Officer?
In this article, Dr Karen Mullen, Chief Medical Officer at Boyds, explores the benefits and value of hiring an interim Chief Medical Officer.

Patient advocacy: the critical role of patient engagement in clinical trials
In this blog, Chris Moore, Senior Clinical Project Manager at Boyds, explores the role of patient and public advocacy and engagement in the clinical trial planning process.

Ada Lovelace Day 2024: empowering women in STEM
To mark Ada Lovelace Day, we spoke to Katherine Bowen, Senior Director of Regulatory Affairs at Boyds, about the inspiration behind her STEM career, how she overcame challenges along the way, and ways to encourage more women to work in STEM.

Don’t fall at the last hurdle: how to select the right eCTD vendor
In the fast-paced world of drug development, navigating the regulatory landscape can feel like running a marathon with hurdles at every turn. One of the critical checkpoints in this race is the submission of electronic Common Technical Documents (eCTD) to the regulatory authorities, such as FDA, MHRA and EMA.